Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 3/2002

01-03-2002

Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane

Authors: Yosuke Kishimoto, Kazuo Yashima, Tsuyoshi Morisawa, Goshi Shiota, Hironaka Kawasaki, Junichi Hasegawa

Published in: Journal of Gastroenterology | Issue 3/2002

Login to get access
Metadata
Title
Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane
Authors
Yosuke Kishimoto
Kazuo Yashima
Tsuyoshi Morisawa
Goshi Shiota
Hironaka Kawasaki
Junichi Hasegawa
Publication date
01-03-2002
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 3/2002
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s005350200019

Other articles of this Issue 3/2002

Journal of Gastroenterology 3/2002 Go to the issue

OriginalPaper

The effects of rabeprazole on parietal cells and enterochromaffin-like cells in rats: a comparison with omeprazole

Editorial

Rabeprazole: quest for the best PPI

Letter to the Editor

Beta-adrenoreceptor agonists for diffuse esophageal spasm

Case report

Tumor thrombi in the portal vein system originating from gastrointestinal tract cancer

Review

Gastrointestinal cancer of the microsatellite mutator phenotype pathway

Case report

Protein-losing gastropathy associated with autoimmune disease: successful treatment with prednisolone
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits